Bacteriophage therapy for drug-resistant Staphylococcus aureus infections
- PMID: 38357445
- PMCID: PMC10864608
- DOI: 10.3389/fcimb.2024.1336821
Bacteriophage therapy for drug-resistant Staphylococcus aureus infections
Abstract
Drug-resistant Staphylococcus aureus stands as a prominent pathogen in nosocomial and community-acquired infections, capable of inciting various infections at different sites in patients. This includes Staphylococcus aureus bacteremia (SaB), which exhibits a severe infection frequently associated with significant mortality rate of approximately 25%. In the absence of better alternative therapies, antibiotics is still the main approach for treating infections. However, excessive use of antibiotics has, in turn, led to an increase in antimicrobial resistance. Hence, it is imperative that new strategies are developed to control drug-resistant S. aureus infections. Bacteriophages are viruses with the ability to infect bacteria. Bacteriophages, were used to treat bacterial infections before the advent of antibiotics, but were subsequently replaced by antibiotics due to limited theoretical understanding and inefficient preparation processes at the time. Recently, phages have attracted the attention of many researchers again because of the serious problem of antibiotic resistance. This article provides a comprehensive overview of phage biology, animal models, diverse clinical case treatments, and clinical trials in the context of drug-resistant S. aureus phage therapy. It also assesses the strengths and limitations of phage therapy and outlines the future prospects and research directions. This review is expected to offer valuable insights for researchers engaged in phage-based treatments for drug-resistant S. aureus infections.
Keywords: antimicrobial resistance; bacteriophage therapy; bacteriophages; drug-resistant Staphylococcus aureus; infection.
Copyright © 2024 Liu, Wang, Zhou, Guo, Yang, Liu, Zhao and Song.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials.Front Cell Infect Microbiol. 2022 Jun 17;12:907314. doi: 10.3389/fcimb.2022.907314. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35782148 Free PMC article. Review.
-
Phages for treatment of Staphylococcus aureus infection.Prog Mol Biol Transl Sci. 2023;200:275-302. doi: 10.1016/bs.pmbts.2023.03.027. Epub 2023 May 3. Prog Mol Biol Transl Sci. 2023. PMID: 37739558
-
Overview of the risks of Staphylococcus aureus infections and their control by bacteriophages and bacteriophage-encoded products.Braz J Microbiol. 2021 Dec;52(4):2031-2042. doi: 10.1007/s42770-021-00566-4. Epub 2021 Jul 12. Braz J Microbiol. 2021. PMID: 34251609 Free PMC article. Review.
-
An experimental study on the lytic bacteriophage MSP15 with wide-spectrum targeting methicillin-resistant Staphylococcus aureus.Virology. 2025 Apr;605:110452. doi: 10.1016/j.virol.2025.110452. Epub 2025 Feb 15. Virology. 2025. PMID: 39986260
-
Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations.Allergy. 2021 Nov;76(11):3446-3458. doi: 10.1111/all.14883. Epub 2021 May 16. Allergy. 2021. PMID: 33930199
Cited by
-
Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Mol Biotechnol. 2025 Jul 9. doi: 10.1007/s12033-025-01466-w. Online ahead of print. Mol Biotechnol. 2025. PMID: 40632445 Review.
-
Beyond antibiotics: mesenchymal stem cells and bacteriophages-new approaches to combat bacterial resistance in wound infections.Mol Biol Rep. 2024 Dec 19;52(1):64. doi: 10.1007/s11033-024-10163-x. Mol Biol Rep. 2024. PMID: 39699690 Review.
-
The Appearance of Antiphage Antibodies in Sera of Patients Treated with Phages.Antibiotics (Basel). 2025 Jan 14;14(1):87. doi: 10.3390/antibiotics14010087. Antibiotics (Basel). 2025. PMID: 39858371 Free PMC article.
-
Genome sequence of staphylococcal phage ESa4 of the genus Rosenblumvirus.Microbiol Resour Announc. 2025 Aug 14;14(8):e0028025. doi: 10.1128/mra.00280-25. Epub 2025 Jul 25. Microbiol Resour Announc. 2025. PMID: 40709939 Free PMC article.
-
Four Novel Caudoviricetes Bacteriophages Isolated from Baltic Sea Water Infect Colonizers of Aurelia aurita.Viruses. 2023 Jul 9;15(7):1525. doi: 10.3390/v15071525. Viruses. 2023. PMID: 37515211 Free PMC article.
References
-
- Aguilar G. R., Swetschinski L. R., Weaver N. D., Ikuta K. S., Mestrovic T., Gray A. P., et al. . (2023). The burden of antimicrobial resistance in the Americas in 2019: A cross-country systematic analysis. Lancet Regional. Health - Americas. 25, 100561. doi: 10.1016/j.lana.2023.100561 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases